Global Gene Therapy Market By Vector Type (Viral Vector(Retroviral, Adeno-associated) and Non – Viral(Oligonucleotides) Vector), By Gene Type (Antigen, Receptor, Growth Factors, Cytokine), By Delivery Method (Ex-Vivo & In Vivo Therapy), By Disease Indication (Ophthalmology, Neurology, Hematology) and Duchenne Muscular Dystrophy), By Distribution Channel (Hospitals, Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- Published date: March 2024
- Report ID: 22161
- Number of Pages: 241
- Format:
-
keyboard_arrow_up
-
-
- Novartis AG Company Profile
- Biogen
- Gilead Science, Inc.
- Spark Therapeutics, Inc.
- Amgen, Inc.
- Jazz Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Spartea Therapeutics
- Sibiono Gene Tech Co, Ltd.
- Orchard Therapeutics
- Bluebird Bio, Inc.
- Sunway Biotech CO, Ltd.
- Applied Genetic Corporation
- Astellas Therapeutics
- Merck & CO, Inc.
- REGENXIBO Inc.
- Sangamo Therapeutics, Inc.
- Cipla Inc.
- Intellia Therapeutics, Inc.
- BioMarin Pharmaceuticals Inc.
- Other Key Players
- settingsSettings
Our Clients
- 22161
- March 2024
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
